|
|
|
| Reducing the Disease Burden of AML with Vor Bio's Dr. Robert Ang | In 2021 on Episode 13, Vor Bio’s President and CEO, Dr. Robert Ang shared data about the company’s lead eHSC product candidate. Dr. Ang is back to talk to Cell & Gene: The Podcast about how Vor has treated 8 patients demonstrating clinical proof of concept and is also in the clinic with a CAR-T that could be used in combination with shielded stem cell transplants. Listen now! |
|
|
|
|
Five attributes are essential for emerging biotech companies to thrive and grow in what will be a challenging financing environment for the foreseeable future. These attributes also serve as a proxy for creating long-term, sustainable value. |
|
|
|
|
|
|
|
|
|
|
|
CONTRIBUTE TO LIFE SCIENCE LEADER |
|
|
|
Think you have a good idea for an article that Life Science Leader readers would find valuable? Read these guidelines first before submitting your idea or your article to our editorial director. |
|
|
Connect With Life Science Leader: |
|
|
|